Investigational Estrogen-Like Compound May Be A Potential Candidate For A Remyelinating Therapy In MS, Study Suggests.

“an investigational estrogen-like compound, induced oligodendrocyte differentiation in vitro, and upregulated oligodendrogenesis genes, making it a potential candidate for a remyelinating therapy in multiple sclerosis (MS),” researchers found. The findings were presented at the Society for Neuroscience meeting. http://www.medpagetoday.com/mastery-of-medicine/neurology-mastery-in-ms/61527